Reaction
Pulmonary Hypoplasia reporting signals
As of the last recalculation, Pulmonary Hypoplasia appears in 785 FAERS reports alongside 17 co-occurring drug terms. The strongest observed disproportionality signal is NEVIRAPINE (PRR 54.1).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Nevirapine | 18 | 54.1 | 54.2 |
| Misoprostol | 19 | 53.0 | 53.1 |
| Dolutegravir Sodium | 17 | 51.1 | 51.1 |
| Zidovudine | 23 | 47.0 | 47.0 |
| Epoetin Alfa | 15 | 34.2 | 34.3 |
| Ritonavir | 34 | 32.2 | 32.2 |
| Captopril | 11 | 30.8 | 30.8 |
| Valsartan Oral | 58 | 30.5 | 30.5 |
| Candesartan Cilexetil | 24 | 24.9 | 25.0 |
| Candesartan | 32 | 24.8 | 24.8 |
| Ritonavir 100 Mg | 13 | 23.4 | 23.5 |
| Goserelin | 11 | 22.0 | 22.0 |
| Olmesartan Medoxomil | 28 | 21.4 | 21.4 |
| Trastuzumab | 51 | 21.0 | 21.0 |
| Tenofovir Disoproxil Fumarate Tablets | 6 | 18.6 | 18.6 |
| Pertuzumab | 12 | 11.9 | 11.9 |
| Paclitaxel (Aibumin-Bound) | 34 | 11.4 | 11.4 |